Sfoglia per Autore
Pegfilgrastim to support chop-r chemotherapy administered every 14 days in the patients (pts) with aggressive b-cell non-hodgkin’s lymphoma (NHL)
2007-01-01 Capochiani, E.; Cupini, S.; Loupakis, F.; Vasile, E.; Fontana, A.; Barbara, C.; Bursi, S.; Landi, L.; Coltelli, L.; Safina, V.; Barletta, M. T.; Baldi, G. G.; Giuntini, N.; LO DICO, M.; Mazzoni, E.; Masi, G.; Falcone, Alfredo
Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
2007-01-01 Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Fornaro, L.; Allegrini, G.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo
Phase III Trial of infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil,Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest(G.O.N.O.)
2007-01-01 Falcone, Alfredo; Ricci, S.; Brunetti, I.; Pfanner, E.; Allegrini, G.; Barbara, C.; Crin, L.; Benedetti, G.; Evangelista, W.; Fanchini, L.; Cortesi, E.; Picone, V.; Vitello, S.; Chiara, S.; Granetto, C.; Porcile, G.; Fioretto, L.; Orlandini, C.; Andreuccetti, M.; Masi, G.
Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC)
2007-01-01 Graziano, F.; Ruzzo, A.; Loupakis, F.; Floriani, I.; Canestrari, E.; Santini, D.; Catalano, V.; Torresi, U.; Bisonni, R.; Masi, G.; Schiavon, G.; Andreoni, F.; Maltese, P.; Giustini, L.; Falcone, Alfredo; Tonini, G.; Rulli, E.; Fontana, A.; Mari, D.; Magnani, M.
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Allegrini, G.; Donati, S.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2008-01-01 Allegrini, G.; Bocci, Guido; Barletta, M.; Fioravanti, A.; DI DESIDERIO, T.; Loupakis, F.; Masi, G.; Baldi, G.; DI MARSICO, R.; DEL TACCA, M.; DI LEO, A.; Brandi, G.; Andreuccetti, M.; Kerbel, R.; Falcone, Alfredo
First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
2008-01-01 Loupakis, F.; Masi, G.; Vasile, E.; Falcone, Alfredo
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
2008-01-01 Fornaro, L.; Masi, G.; Bursi, S.; Loupakis, F.; Vasile, E.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; DI PAOLO, Antonello; Bocci, Guido; DEL TACCA, M.; Falcone, Alfredo
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction
2008-01-01 Bocci, Guido; DI PAOLO, Antonello; Masi, G.; Fornaro, L.; Allegrini, G.; Falcone, Alfredo; DEL TACCA, M.; Danesi, Romano
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment
2008-01-01 Irene, Stasi; Fotios, Loupakis; Luca, Pollina; Masi, Gianluca; Nicola, Funel; Mario, Scartozzi; Petrini, Iacopo; Daniele, Santini; Stefano, Cascinu; Falcone, Alfredo
K-RAS status in primary colorectal tumours correlate with K-RAS status in related metastatic sites: implications for treatment with anti-EGFR antibodies in clinical setting
2008-01-01 Santini, D.; Loupakis, F.; Vincenzi, B.; Perrone, G.; Graziano, F.; Floriani, I.; Maltese, P.; Stasi, I.; Canestrari, E.; Masi, G.; ONETTI MUDA, A.; Magnani, M.; Falcone, Alfredo; Ruzzo, A.; Tonini, G.
Phase II study of irinotecan, oxaliplatin and infusional 5FU/LV (GONO-FOLFOXIRI) plus bevacizumab (BV) as first-line treatment in metastatic colorectal cancer (MCRC)
2008-01-01 Masi, G.; Loupakis, F.; Vasile, E.; Cupini, S.; Fornaro, L.; Baldi, G. G.; Stasi, I.; Salvatore, L.; Ciarlo, A.; Cavaciocchi, D.; Ciprotti, M.; Puglisi, M.; Rondini, M.; Puccinelli, P.; Granetto, C.; DI DONATO, S.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment
2008-01-01 Loupakis, F.; Stasi, I.; Pollina, L.; Masi, G.; Baldi, G.; Fornaio, L.; Schiavon, G.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Funel, N.; Campani, Daniela; Tonini, G.; Cascinu, S.; Falcone, Alfredo
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
2008-01-01 Santini, D.; Loupakis, F.; Vincenzi, B.; Floriani, I.; Stasi, I.; Canestrari, E.; Rulli, E.; Maltese, P. E.; Andreoni, F.; Masi, G.; Graziano, F.; Baldi, G. G.; Salvatore, L.; Russo, A.; Perrone, G.; Tommasino, M. R.; Magnani, M.; Falcone, Alfredo; Tonini, G.; Ruzzo, A.
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS)
2008-01-01 Loupakis, F.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Falcone, Alfredo
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach
2008-01-01 Loupakis, F.; Vasile, E.; Santini, D.; Masi, G.; Falcone, Alfredo; Graziano, F.
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS)
2008-01-01 Loupakis, F.; Stasi, I.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Funel, N.; Fornaro, L.; Baldi, G. G.; Salvatore, L.; Cupini, S.; Petrini, Iacopo; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Ricci, S.; Tonini, G.; Magnani, M.; Falcone, Alfredo
Insulin-like growth factor-1 (IGF-1) correlates with clinical outcome in metastatic colorectal patients treated with irinotecan/cetuximab combination
2008-01-01 Pierantoni, C.; Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Loupakis, F.; Masi, G.; Berardi, R.; Zaniboni, A.; Quadri, A.; Zorzi, F.; Biscotti, T.; Labianca, R.; Falcone, Alfredo; Cascinu, S.
Chemotherapy without monoclonal antibodies in the treatment of metastatic colorectal cancer: Role of Triplets
2008-01-01 Falcone, Alfredo; Loupakis, F.; Vasile, E.; Masi, G.
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts)
2008-01-01 Masi, G.; Loupakis, F.; Fornaio, L.; Baldi, G.; Cupini, S.; DI DONATO, S.; Ferraldeschi, R.; Sonaglio, C.; Granetto, C.; Falcone, Alfredo
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Pegfilgrastim to support chop-r chemotherapy administered every 14 days in the patients (pts) with aggressive b-cell non-hodgkin’s lymphoma (NHL) | 1-gen-2007 | Capochiani, E.; Cupini, S.; Loupakis, F.; Vasile, E.; Fontana, A.; Barbara, C.; Bursi, S.; Landi, L.; Coltelli, L.; Safina, V.; Barletta, M. T.; Baldi, G. G.; Giuntini, N.; LO DICO, M.; Mazzoni, E.; Masi, G.; Falcone, Alfredo | |
Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) | 1-gen-2007 | Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Fornaro, L.; Allegrini, G.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo | |
Phase III Trial of infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil,Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest(G.O.N.O.) | 1-gen-2007 | Falcone, Alfredo; Ricci, S.; Brunetti, I.; Pfanner, E.; Allegrini, G.; Barbara, C.; Crin, L.; Benedetti, G.; Evangelista, W.; Fanchini, L.; Cortesi, E.; Picone, V.; Vitello, S.; Chiara, S.; Granetto, C.; Porcile, G.; Fioretto, L.; Orlandini, C.; Andreuccetti, M.; Masi, G. | |
Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC) | 1-gen-2007 | Graziano, F.; Ruzzo, A.; Loupakis, F.; Floriani, I.; Canestrari, E.; Santini, D.; Catalano, V.; Torresi, U.; Bisonni, R.; Masi, G.; Schiavon, G.; Andreoni, F.; Maltese, P.; Giustini, L.; Falcone, Alfredo; Tonini, G.; Rulli, E.; Fontana, A.; Mari, D.; Magnani, M. | |
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) | 1-gen-2007 | Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Allegrini, G.; Donati, S.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo | |
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2008 | Allegrini, G.; Bocci, Guido; Barletta, M.; Fioravanti, A.; DI DESIDERIO, T.; Loupakis, F.; Masi, G.; Baldi, G.; DI MARSICO, R.; DEL TACCA, M.; DI LEO, A.; Brandi, G.; Andreuccetti, M.; Kerbel, R.; Falcone, Alfredo | |
First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? | 1-gen-2008 | Loupakis, F.; Masi, G.; Vasile, E.; Falcone, Alfredo | |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer | 1-gen-2008 | Fornaro, L.; Masi, G.; Bursi, S.; Loupakis, F.; Vasile, E.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; DI PAOLO, Antonello; Bocci, Guido; DEL TACCA, M.; Falcone, Alfredo | |
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction | 1-gen-2008 | Bocci, Guido; DI PAOLO, Antonello; Masi, G.; Fornaro, L.; Allegrini, G.; Falcone, Alfredo; DEL TACCA, M.; Danesi, Romano | |
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Irene, Stasi; Fotios, Loupakis; Luca, Pollina; Masi, Gianluca; Nicola, Funel; Mario, Scartozzi; Petrini, Iacopo; Daniele, Santini; Stefano, Cascinu; Falcone, Alfredo | |
K-RAS status in primary colorectal tumours correlate with K-RAS status in related metastatic sites: implications for treatment with anti-EGFR antibodies in clinical setting | 1-gen-2008 | Santini, D.; Loupakis, F.; Vincenzi, B.; Perrone, G.; Graziano, F.; Floriani, I.; Maltese, P.; Stasi, I.; Canestrari, E.; Masi, G.; ONETTI MUDA, A.; Magnani, M.; Falcone, Alfredo; Ruzzo, A.; Tonini, G. | |
Phase II study of irinotecan, oxaliplatin and infusional 5FU/LV (GONO-FOLFOXIRI) plus bevacizumab (BV) as first-line treatment in metastatic colorectal cancer (MCRC) | 1-gen-2008 | Masi, G.; Loupakis, F.; Vasile, E.; Cupini, S.; Fornaro, L.; Baldi, G. G.; Stasi, I.; Salvatore, L.; Ciarlo, A.; Cavaciocchi, D.; Ciprotti, M.; Puglisi, M.; Rondini, M.; Puccinelli, P.; Granetto, C.; DI DONATO, S.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo | |
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Loupakis, F.; Stasi, I.; Pollina, L.; Masi, G.; Baldi, G.; Fornaio, L.; Schiavon, G.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Funel, N.; Campani, Daniela; Tonini, G.; Cascinu, S.; Falcone, Alfredo | |
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice | 1-gen-2008 | Santini, D.; Loupakis, F.; Vincenzi, B.; Floriani, I.; Stasi, I.; Canestrari, E.; Rulli, E.; Maltese, P. E.; Andreoni, F.; Masi, G.; Graziano, F.; Baldi, G. G.; Salvatore, L.; Russo, A.; Perrone, G.; Tommasino, M. R.; Magnani, M.; Falcone, Alfredo; Tonini, G.; Ruzzo, A. | |
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) | 1-gen-2008 | Loupakis, F.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Falcone, Alfredo | |
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach | 1-gen-2008 | Loupakis, F.; Vasile, E.; Santini, D.; Masi, G.; Falcone, Alfredo; Graziano, F. | |
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) | 1-gen-2008 | Loupakis, F.; Stasi, I.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Funel, N.; Fornaro, L.; Baldi, G. G.; Salvatore, L.; Cupini, S.; Petrini, Iacopo; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Ricci, S.; Tonini, G.; Magnani, M.; Falcone, Alfredo | |
Insulin-like growth factor-1 (IGF-1) correlates with clinical outcome in metastatic colorectal patients treated with irinotecan/cetuximab combination | 1-gen-2008 | Pierantoni, C.; Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Loupakis, F.; Masi, G.; Berardi, R.; Zaniboni, A.; Quadri, A.; Zorzi, F.; Biscotti, T.; Labianca, R.; Falcone, Alfredo; Cascinu, S. | |
Chemotherapy without monoclonal antibodies in the treatment of metastatic colorectal cancer: Role of Triplets | 1-gen-2008 | Falcone, Alfredo; Loupakis, F.; Vasile, E.; Masi, G. | |
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts) | 1-gen-2008 | Masi, G.; Loupakis, F.; Fornaio, L.; Baldi, G.; Cupini, S.; DI DONATO, S.; Ferraldeschi, R.; Sonaglio, C.; Granetto, C.; Falcone, Alfredo |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile